http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7332480-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fdaa64756184e715af6cb25ebc318917 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7016 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7016 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H11-00 |
| filingDate | 2004-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12bc3774a77f8f7ff8fb522fe4fcc262 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9a49a9452fc7ae3361242e895f9056e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bcc91c3fc93f1d55a00410adc4b646d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ececb392fbfafc93622e804b84700e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23c5733f5ba587051dc16269de29924d |
| publicationDate | 2008-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-7332480-B2 |
| titleOfInvention | Compositions for the regulation of cytokine activity |
| abstract | Substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, including compositions containing same and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of Tumor Necrosis Factor Alpha (TNF-α) can be either inhibited or augmented selectively by administration to the host of effective amounts of substances or their compositions comprising specific oligosaccharides in substantially purified form. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF-α. The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of up to about 5-8 days, preferably once a week. |
| priorityDate | 1992-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 829.